DexCom (DXCM) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
DexCom (DXCM) PT Raised to $100 at Piper Jaffray
August 3, 2016 7:59 AM EDTPiper Jaffray analyst Brooks West reiterated an Overweight rating and raised his price target on DexCom (NASDAQ: DXCM) to $100.00 (from $93.00) on German reimbursement and positive FDA Panel.
West commented, "DexCom reported $137.3M (+47%) in 2Q16 revenue, ahead of consensus $132.5M but below the... More



